Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

170 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer.
Baty F, Rothschild S, Früh M, Betticher D, Dröge C, Cathomas R, Rauch D, Gautschi O, Bubendorf L, Crowe S, Zappa F, Pless M, Brutsche M; Swiss Group for Clinical Cancer Research. Baty F, et al. Among authors: betticher d. PLoS One. 2013 Sep 10;8(9):e72966. doi: 10.1371/journal.pone.0072966. eCollection 2013. PLoS One. 2013. PMID: 24039832 Free PMC article.
Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial.
Betticher DC, Hsu Schmitz SF, Tötsch M, Hansen E, Joss C, von Briel C, Schmid RA, Pless M, Habicht J, Roth AD, Spiliopoulos A, Stahel R, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny T, Ris HB. Betticher DC, et al. J Clin Oncol. 2003 May 1;21(9):1752-9. doi: 10.1200/JCO.2003.11.040. J Clin Oncol. 2003. PMID: 12721251 Clinical Trial.
[Molecular therapy in lung cancer].
Gautschi O, Betticher DC. Gautschi O, et al. Among authors: betticher dc. Ther Umsch. 2004 Jun;61(6):365-71. doi: 10.1024/0040-5930.61.6.365. Ther Umsch. 2004. PMID: 15253161 Review. German.
Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK).
Ghielmini M, Schmitz SF, Cogliatti S, Bertoni F, Waltzer U, Fey MF, Betticher DC, Schefer H, Pichert G, Stahel R, Ketterer N, Bargetzi M, Cerny T; Swiss Group for Clinical Cancer Research. Ghielmini M, et al. J Clin Oncol. 2005 Feb 1;23(4):705-11. doi: 10.1200/JCO.2005.04.164. Epub 2004 Dec 14. J Clin Oncol. 2005. PMID: 15598978 Clinical Trial.
Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability.
Smith SL, Bowers NL, Betticher DC, Gautschi O, Ratschiller D, Hoban PR, Booton R, Santibáñez-Koref MF, Heighway J. Smith SL, et al. Among authors: betticher dc. Br J Cancer. 2005 Sep 19;93(6):719-29. doi: 10.1038/sj.bjc.6602779. Br J Cancer. 2005. PMID: 16222316 Free PMC article.
Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients.
Gautschi O, Hugli B, Ziegler A, Bigosch C, Bowers NL, Ratschiller D, Jermann M, Stahel RA, Heighway J, Betticher DC. Gautschi O, et al. Among authors: betticher dc. Lung Cancer. 2006 Mar;51(3):303-11. doi: 10.1016/j.lungcan.2005.10.025. Epub 2006 Jan 10. Lung Cancer. 2006. PMID: 16406195
Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study.
Betticher DC, Hsu Schmitz SF, Tötsch M, Hansen E, Joss C, von Briel C, Schmid RA, Pless M, Habicht J, Roth AD, Spiliopoulos A, Stahel R, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny T, Ris HB; Swiss Group for Clinical Cancer Research (SAKK). Betticher DC, et al. Br J Cancer. 2006 Apr 24;94(8):1099-106. doi: 10.1038/sj.bjc.6603075. Br J Cancer. 2006. PMID: 16622435 Free PMC article. Clinical Trial.
Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03.
D'Addario G, Rauch D, Stupp R, Pless M, Stahel R, Mach N, Jost L, Widmer L, Tapia C, Bihl M, Mayer M, Ribi K, Lerch S, Bubendorf L, Betticher DC. D'Addario G, et al. Among authors: betticher dc. Ann Oncol. 2008 Apr;19(4):739-45. doi: 10.1093/annonc/mdm564. Epub 2007 Dec 19. Ann Oncol. 2008. PMID: 18096565 Free article. Clinical Trial.
170 results